TrialInvestigational new drugs2017

Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.

Ravi Salgia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.